← Back to Clinical Trials
Recruiting NCT06760572

NCT06760572 Airway Data Collection With the Entarik Feeding Tube System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06760572
Status Recruiting
Phase
Sponsor Theranova, L.L.C.
Condition Healthy
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-02-13
Primary Completion 2025-12-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Airway insertion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-02-13 with a primary completion date of 2025-12-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the airway detection performance of the Entarik Feeding Tube System, and to collect data when the Entarik Feeding Tube is in the Airway for device development.

Eligibility Criteria

Inclusion Criteria: 1. At least 18 years old. 2. Able to provide informed consent. 3. Adults scheduled to undergo a bronchoscopy procedure who will be intubated as part of the standard of care. Exclusion Criteria: 1. Known major upper airway malformation. 2. Presence of clinically significant respiratory infection. 3. Known bleeding disorder. 4. Currently pregnant. 5. Current basilar skull fracture. 6. Known sensitivities or allergies to the feeding tube components. 7. Deemed unsuitable for enrollment in study by the investigator based on subject's history (e.g., active anticoagulation therapy) or physical examination.

Contact & Investigator

Central Contact

Aaron Miller

✉ clinicalstudy@theranova.com

📞 415-926-8616

Principal Investigator

Daniel Burnett, MD

STUDY DIRECTOR

Theranova, LLC

Frequently Asked Questions

Who can join the NCT06760572 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06760572 currently recruiting?

Yes, NCT06760572 is actively recruiting participants. Contact the research team at clinicalstudy@theranova.com for enrollment information.

Where is the NCT06760572 trial being conducted?

This trial is being conducted at Philadelphia, United States.

Who is sponsoring the NCT06760572 clinical trial?

NCT06760572 is sponsored by Theranova, L.L.C.. The principal investigator is Daniel Burnett, MD at Theranova, LLC. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology